Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00283049 · ClinicalTrials.gov registry record · Phase 4
Insulin Glargine Injection Treatment in Place of Thiazolidinedione (TZD), Sulfonylurea, or Metformin in Triple Agent Therapy for Type 2 Diabetes Mellitus (T2DM) Adult Subjects With Unsatisfactory Control
A Phase 4 study, sponsored by Sanofi.
- Terminated
- Registry status
- Phase 4
- Development phase
- 390
- Enrollment target
NCT00283049 is a Phase 4 study that was terminated before completion, run by Sanofi. The registered enrollment target is 390 participants.
The verdict
NCT00283049, a Phase 4 study, was terminated before completion, sponsored by Sanofi.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 390 participants
- Enrollment target
Study Summary
The purpose of this study is to compare the change in hemoglobin A1c (HbA1c) from baseline to Week 12 between the 3 treatment arms.
Interventions
- DRUG Insulin Glargine
- DRUG Insulin Glulisine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 390 participants |
| Start Date | 2006-02 |
| Est. Completion | 2008-11 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00283049
The ClinicalTrials.gov registry entry for NCT00283049 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 390 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Sanofi, which has 713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Insulin Glargine is the first listed.
NCT00283049 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00283049 about?
NCT00283049 is a clinical study titled "Insulin Glargine Injection Treatment in Place of Thiazolidinedione (TZD), Sulfonylurea, or Metformin in Triple Agent Therapy for Type 2 Diabetes Mellitus (T2DM) Adult Subjects With Unsatisfactory Control". The purpose of this study is to compare the change in hemoglobin A1c (HbA1c) from baseline to Week 12 between the 3 treatment arms.
What is the current status of trial NCT00283049?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 390 participants. The study started on 2006-02. Estimated completion is 2008-11.
What interventions are being tested in trial NCT00283049?
The interventions under investigation include: Insulin Glargine (DRUG), Insulin Glulisine (DRUG).
Who is sponsoring clinical trial NCT00283049?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.